Phase 3 Readout~month

Phase 3 Topline: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic

Indication
C3 Glomerulopathy; C3G; IC-MPGN

Other upcoming events for APLS

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac
Phase 3 ReadoutPhase 3 Topline: A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Con
Patent ExpiryPatent/Exclusivity Expiry: SYFOVRE
Patent ExpiryPatent/Exclusivity Expiry: EMPAVELI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic — APLS Phase 3 Readout | BioSniper